within Pharmacolibrary.Drugs.ATC.L;

model L01FX14
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.015000000000000001,
    adminDuration  = 600,
    adminMass      = 0.0018,
    adminCount     = 1,
    Vd             = 0.00315,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b, used for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It is approved for medical use in several regions including the US and EU.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult patients with relapsed/refractory B-cell lymphoma. Parameters are for acMMAE (antibody-conjugated monomethyl auristatin E component) in predominantly older adults (~61 years, both sexes).</p><h4>References</h4><ol><li><p>Shemesh, CS, et al., &amp; Lu, D (2020). Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. <i>Cancer chemotherapy and pharmacology</i> 85(5) 831–842. DOI:<a href=&quot;https://doi.org/10.1007/s00280-020-04054-8&quot;>10.1007/s00280-020-04054-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32222808/&quot;>https://pubmed.ncbi.nlm.nih.gov/32222808</a></p></li><li><p>Kinoshita, T, et al., &amp; Tobinai, K (2021). Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study. <i>Japanese journal of clinical oncology</i> 51(1) 70–77. DOI:<a href=&quot;https://doi.org/10.1093/jjco/hyaa169&quot;>10.1093/jjco/hyaa169</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33029633/&quot;>https://pubmed.ncbi.nlm.nih.gov/33029633</a></p></li><li><p>Yip, V, et al., &amp; Shen, BQ (2021). Preclinical Characterization of the Distribution, Catabolism, and Elimination of a Polatuzumab Vedotin-Piiq (POLIVY. <i>Journal of clinical medicine</i> 10(6) –. DOI:<a href=&quot;https://doi.org/10.3390/jcm10061323&quot;>10.3390/jcm10061323</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33806916/&quot;>https://pubmed.ncbi.nlm.nih.gov/33806916</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01FX14;
